184 related articles for article (PubMed ID: 10928383)
21. Radiometal targeted tumor diagnosis and therapy with peptide hormones.
Zwanziger D; Beck-Sickinger AG
Curr Pharm Des; 2008; 14(24):2385-400. PubMed ID: 18781989
[TBL] [Abstract][Full Text] [Related]
22. Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs.
Mariani G; Erba PA; Signore A
J Nucl Med; 2006 Dec; 47(12):1904-7. PubMed ID: 17138731
[No Abstract] [Full Text] [Related]
23. Recent developments in 99Tcm-labelled peptide-based radiopharmaceuticals: an overview.
Okarvi SM
Nucl Med Commun; 1999 Dec; 20(12):1093-112. PubMed ID: 10664991
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
Behr TM; Béhé M; Becker W
Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
[TBL] [Abstract][Full Text] [Related]
25. Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents.
Harris TD; Cheesman E; Harris AR; Sachleben R; Edwards DS; Liu S; Bartis J; Ellars C; Onthank D; Yalamanchili P; Heminway S; Silva P; Robinson S; Lazewatsky J; Rajopadhye M; Barrett J
Bioconjug Chem; 2007; 18(4):1266-79. PubMed ID: 17579472
[TBL] [Abstract][Full Text] [Related]
26. Radiolabelled regulatory peptides for imaging and therapy.
Breeman WA; Kwekkeboom DJ; de Blois E; de Jong M; Visser TJ; Krenning EP
Anticancer Agents Med Chem; 2007 May; 7(3):345-57. PubMed ID: 17504160
[TBL] [Abstract][Full Text] [Related]
27. Peptide radiopharmaceuticals for diagnosis and therapy.
Signore A; Annovazzi A; Chianelli M; Corsetti F; Van de Wiele C; Watherhouse RN
Eur J Nucl Med; 2001 Oct; 28(10):1555-65. PubMed ID: 11685500
[TBL] [Abstract][Full Text] [Related]
28. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy.
van Hagen PM; Breeman WA; Bernard HF; Schaar M; Mooij CM; Srinivasan A; Schmidt MA; Krenning EP; de Jong M
Int J Cancer; 2000 Aug; 90(4):186-98. PubMed ID: 10993959
[TBL] [Abstract][Full Text] [Related]
30. Peptide receptor imaging and therapy.
Kwekkeboom D; Krenning EP; de Jong M
J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
[TBL] [Abstract][Full Text] [Related]
31. Radiolabeled peptides in diagnosis and therapy.
Weiner RE; Thakur ML
Semin Nucl Med; 2001 Oct; 31(4):296-311. PubMed ID: 11710772
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2010 Apr; 37(3):277-88. PubMed ID: 20346867
[TBL] [Abstract][Full Text] [Related]
33. Rationale for the use of radiolabelled peptides in diagnosis and therapy.
Koopmans KP; Glaudemans AW
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S4-10. PubMed ID: 22388630
[TBL] [Abstract][Full Text] [Related]
34. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
35. Relationship between neutrophil-binding affinity and suitability for infection imaging: comparison of (99m)Tc-labeled NAP-2 (CXCL-7) and 3 C-terminally truncated isoforms.
Rennen HJ; Frielink C; Brandt E; Zaat SA; Boerman OC; Oyen WJ; Corstens FH
J Nucl Med; 2004 Jul; 45(7):1217-23. PubMed ID: 15235069
[TBL] [Abstract][Full Text] [Related]
36. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy.
Panigone S; Nunn AD
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):310-21. PubMed ID: 17043628
[TBL] [Abstract][Full Text] [Related]
37. Radiolabeled regulatory peptides for imaging and therapy.
Nanda PK; Lane SR; Retzloff LB; Pandey US; Smith CJ
Curr Opin Endocrinol Diabetes Obes; 2010 Feb; 17(1):69-76. PubMed ID: 19901831
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
Zhang H; Chen J; Waldherr C; Hinni K; Waser B; Reubi JC; Maecke HR
Cancer Res; 2004 Sep; 64(18):6707-15. PubMed ID: 15374988
[TBL] [Abstract][Full Text] [Related]
39. The Influence of Different Spacers on Biological Profile of Peptide Radiopharmaceuticals for Diagnosis and Therapy of Human Cancers.
Farahani AM; Maleki F; Sadeghzadeh N
Anticancer Agents Med Chem; 2020; 20(4):402-416. PubMed ID: 31889492
[TBL] [Abstract][Full Text] [Related]
40. Radiolabeled carbohydrated somatostatin analogs: a review of the current status.
Wester HJ; Schottelius M; Poethko T; Bruus-Jensen K; Schwaiger M
Cancer Biother Radiopharm; 2004 Apr; 19(2):231-44. PubMed ID: 15186604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
